Toshiki Kano

Toshiki Kano

Auto-generated profile, based on publicly available information

Toshiki Kano

Department of Nephrology Juntendo University Faculty of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in Nephrology
Verified
Journal Article
Open access
JKJin Sug Kim
Jin Sug Kim
HSHitoshi Suzuki
Hitoshi Suzuki
YFYusuke Fukao
Yusuke Fukao
TKToshiki Kano
Toshiki Kano
MNMaiko Nakayama
Maiko Nakayama
YSYusuke Suzuki
Yusuke Suzuki
Aim: IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, yet its pathogenesis remains incompletely understood. B cell activating factor (BAFF), a TNF family member involved in B cell activation and IgA class switching, has been proposed as a potential pathogenic factor in IgAN. However, its role in disease progression is unclear. This study aimed to investigate the pathological role of BAFF in IgAN using grouped ddY (gddY) mice, a spontaneous murine model of IgAN. Methods: gddY mice were treated with anti‐BAFF monoclonal antibody (anti‐BAFF Ab) or PBS via intraperitoneal injection twice a week for 4 weeks. Urinary albumin, serum immunoglobulins, and IgA‐IgG immune complex were measured pre‐ and post‐treatment. Serum levels of aberrantly glycosylated IgA were quantified using specific lectin‐based assays. Glomerular IgA and C3 depositions were evaluated by immunofluorescence, and B cell populations in spleen and bone marrow were analysed by flowcytometry. Results: Anti‐BAFF Ab treatment significantly reduced serum IgA, IgG, and IgM levels as compared with PBS treatment ( p < 0.001, p = 0.003, and p = 0.002, respectively). However, it did not affect serum aberrantly glycosylated IgA, IgA‐IgG immune complex, and urinary albumin excretion. Glomerular depositions of IgA and C3 as well as B cell population in the spleen and bone marrow were also not affected by anti‐BAFF Ab treatment. Conclusion: BAFF inhibition reduces general immunoglobulin levels but does not impact nephritogenic IgA production or disease progression in murine IgAN. These findings suggest that BAFF‐dependent IgA production may not be involved in the pathogenesis of IgAN.

25 February 2025 in Nephrology
Verified
Journal Article
Open access
TKToshiki Kano
Toshiki Kano
HIHiroaki Io
Hiroaki Io
YSYu Sasaki
Yu Sasaki
MMMasahiro Muto
Masahiro Muto
SMSayaka Muto
Sayaka Muto
YSYusuke Suzuki
Yusuke Suzuki
Atypical hemolytic uremic syndrome is a thrombotic microangiopathy caused by the abnormal activation of the alternative complement pathway. Mutations in complement‐related genes and autoantibodies against complement regulators are involved in the pathogenesis of this condition; the frequency of, and prognosis of patients harbouring, each genetic mutation varies based on the region and race. Complement factor I (CFI) mutations have been observed in 4%–8% of cases in Europe; however, they have not yet been reported in Japan. We present the first Japanese case of atypical hemolytic uremic syndrome in a patient harbouring a CFI mutation. An 83‐year‐old female patient presented with severe acute kidney injury, thrombocytopenia, and hemolytic anaemia following a femoral neck fracture. Plasma exchange and haemodialysis were initiated, resulting in improved kidney function and platelet count. However, the platelet count decreased when plasma exchange was discontinued. Therefore, we administered ravulizumab, an anti‐complement 5 monoclonal antibody, which led to the maintenance of stable kidney function and platelet count. Genetic analysis revealed a CFI mutation, and the patient was treated with ravulizumab for 2 years without relapse. Individuals diagnosed with atypical hemolytic uremic syndrome harbouring CFI mutations experience poor outcomes, including low rates of remission, high rates of mortality, and progression to end‐stage kidney disease. Our case serves as a crucial example demonstrating how prompt identification and appropriate management can lead to better patient outcomes.

24 December 2025 in Kidney360
Verified
Journal Article
Open access
JKJay J. Kuo
Jay J. Kuo
JWJoyce Wu
Joyce Wu
MGMarvin G. Gunawan
Marvin G. Gunawan
MMMark T. McConnell
Mark T. McConnell
JLJeff Lester
Jeff Lester
JCJennifer H. Cox
Jennifer H. Cox
Key Points: In human renal mesangial cells stimulated with endothelin-1, atrasentan reduced mesangial cell proliferation and matrix expansion. Atrasentan reduced kidney injury in two preclinical models of IgA nephropathy. These findings support the therapeutic potential of atrasentan to treat IgA nephropathy; clinical studies of atrasentan are ongoing. Background: IgA nephropathy (IgAN) is the leading cause of primary GN and carries a high risk of progression to ESKD. Endothelin-1 type A (ET A ) receptor activation may be a key driver of proteinuria, inflammation, and fibrosis in patients with kidney diseases. Atrasentan, a highly potent and highly selective antagonist of the ET A receptor, demonstrated a statistically significant and clinically meaningful proteinuria reduction of 36.1% (95% confidence interval, 26.4% to 44.6%; P < 0.001) relative to placebo, at week 36 in the ongoing Atrasentan in Patients With IgA Nephropathy (ALIGN) phase 3 trial. Based on these data, atrasentan is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Methods: We explored the biologic effects and changes in gene transcription with atrasentan in cultured human renal mesangial cells, grouped ddY mouse model of IgAN, and Wistar rats injected with anti-Thy1.1 (CD90) antibody to induce mesangial injury and mesangioproliferative GN. The effect of atrasentan on proteinuria and kidney gene transcriptome was evaluated in both animal models, and histologic and morphometric assessments of rat kidneys were conducted. Results: In separate transcriptomics analyses of all three models, atrasentan reversed gene expression changes related to cell proliferation, proinflammatory, and profibrotic signatures. In human renal mesangial cells stimulated with endothelin-1, atrasentan reduced mesangial cell proliferation and matrix expansion. After 7 days, atrasentan treatment in the mesangioproliferative GN rat model diminished renal mesangial hypercellularity and matrix expansion, decreased glomerular and tubulointerstitial structural alterations, and significantly reduced proteinuria. In grouped ddY mice, atrasentan treatment for 4 days significantly reduced mean albuminuria by >60%. Conclusions: The acute mechanistic effects of atrasentan demonstrated in vitro and in vivo support the therapeutic potential of atrasentan in IgAN. The ongoing Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY) and Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy (ASSIST) phase 2 trials, and the ALIGN phase 3 trial in patients with IgAN will further evaluate the translation of these mechanistic effects to the clinical efficacy and safety of atrasentan.

22 May 2026 in Kidney360
Verified
Journal Article
Open access
RKRina Kato
Rina Kato
HSHitoshi Suzuki
Hitoshi Suzuki
RARyosuke Aoki
Ryosuke Aoki
AKAyako Koizumi
Ayako Koizumi
YFYusuke Fukao
Yusuke Fukao
YSYusuke Suzuki
Yusuke Suzuki
Key Points: Serum IgM-free apoptosis inhibitor of macrophage reflects disease activity in human IgA nephropathy. Glomerular apoptosis inhibitor of macrophage deposition was colocalized with mesangial IgA and reflected the acute glomerular injuries by complement activation. Multivariate Cox regression analysis revealed serum IgM-free apoptosis inhibitor of macrophage as an independent predictor of hematuria remission in patients. Background: IgA nephropathy is characterized by mesangial deposits of IgA1-containing immune complex with complement 3. Our previous study demonstrated that apoptosis inhibitor of macrophage (AIM) plays a critical role in in situ IgA-containing immune complex formation and subsequent complement activation in murine IgA nephropathy. We further evaluated the clinicopathologic role of AIM in human IgA nephropathy. Methods: We enrolled 77 patients with IgA nephropathy, five patients with thin basement membrane disease as disease controls, and 40 age-matched healthy individuals as healthy controls. We analyzed the association between serum IgM-free AIM (sAIM)/glomerular AIM (gAIM) deposition area and clinicopathologic features. Results: sAIM level was higher in patients with IgA nephropathy at diagnosis than in disease and healthy controls (1.02±0.49 versus 0.56±0.19 versus 0.57±0.20 µ g/ml), significantly decreased to 0.67±0.44 µ g/ml after tonsillectomy and steroid pulse therapy, and was associated with serum IgA ( r 2 =0.23) and IgA–IgG immune complex levels ( r 2 =0.12). gAIM was colocalized with mesangial IgA and high intensity of gAIM was associated with the degree of hematuria (30–49 versus 10–19 per high-power field) and acute lesions, including those with Oxford classification scores of endocapillary hypercellularity (E1 3% versus E0 2%) and crescent formation (C1 3% versus C0 2%). Furthermore, gAIM deposition was positively correlated with glomerular complement 3 deposition ( r 2 =0.54). Multivariate Cox regression analysis revealed sAIM as an independent predictor of hematuria remission (hazard ratio, 1.86; 95% confidence interval, 1.03 to 3.15). According to Kaplan–Meier analysis, patients with larger reduction of sAIM (≥0.45 µ g/ml) after tonsillectomy and steroid pulse therapy showed a significantly improved hematuria (6 versus 9 months). Conclusions: We suggest that IgA nephropathy patients with high sAIM levels have high disease activity and patients with high intensity of gAIM deposition have acute glomerular injuries leading to hematuria.

23 August 2025 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
JNJunichiro Nakata
Junichiro Nakata
HFHaruna Fukuzaki
Haruna Fukuzaki
TMTakuya Maeda
Takuya Maeda
KSKai Suzuki
Kai Suzuki
TKToshiki Kano
Toshiki Kano
YSYusuke Suzuki
Yusuke Suzuki